Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone

Naoko Akitake, Masaki Shiota*, Hirofumi Obata, Ario Takeuchi, Eiji Kashiwagi, Kenjiro Imada, Keijiro Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

1. Introduction

Prostate cancer is the second most common cancer and the second leading cause of cancer-related mortality among patients in developed countries.1 Radical prostatectomy (RP) has been the gold standard treatment for clinically localized prostate cancer.2 Though most patients with prostate cancer are successfully treated with RP, approximately 17–53% of patients experience biochemical recurrence (BCR) within 10 years.3 4 Therefore, multimodal approaches such as neoadjuvant or adjuvant therapy combined with RP have been investigated to improve the oncological outcome for high-risk prostate cancer.3 Among these approaches, adjuvant radiotherapy5 and adjuvant androgen-deprivation therapy (ADT)6 have been proven to improve overall survival (OS) in prostate cancer invasive to seminal vesicle and metastatic to regional lymph node, respectively. ADT reduces androgen production and inhibits androgen action; it is the standard therapy for metastatic prostate cancer.8 Although the hypothesis that neoadjuvant ADT may improve oncological outcome has been investigated, most randomized studies failed to show improved BCR-free survival as well as OS after RP, although pathological stage and surgical margin status have been improved by neoadjuvant ADT.9–11 Consistent with these findings, in systematic review and meta-analysis, OS was not improved by neoadjuvant ADT with RP.12 With the aim of improving outcome, several studies are investigating whether the combination of novel agents such as abiraterone acetate, enzalutamide, and taxanes with ADT before RP improves outcome; however, no results have been obtained showing improved prognosis.
The low impact of neoadjuvant ADT on BCR may partially be due to the delay before surgical intervention, which may result in cancer progression during ADT treatment in the subgroup of patients that may be less sensitive to ADT. Therefore, identifying the subgroup sensitive to neoadjuvant ADT would be useful. In this study, we performed subgroup analyses among patients who had undergone RP with or without neoadjuvant ADT on outcome.

2. Materials and methods

2.1. Patients

This study enrolled 711 patients who were histopathologically diagnosed with adenocarcinoma of the prostate and treated with open RP, laparoscopic RP, or robot-assisted laparoscopic RP as the primary treatment for prostate cancer at Kyushu University Hospital (Fukuoka, Japan) between 2000 and 2013. Patients diagnosed with metastasis by imaging modalities including computed tomography scan and bone scan and patients with a history of neoadjuvant/adjuvant radiotherapy or chemotherapy and adjuvant ADT against prostate cancer were excluded. Lymph node dissection for the bilateral regions along the external and internal iliac vessels and within the obturator fossa was performed according to the operation method, and the risk of lymph node involvement was determined by preoperative cancer risk. This study was approved by the institutional review board.

2.2. Data collection

Available data for patients enrolled in this investigation included age, prostate-specific antigen (PSA) level at diagnosis, clinical and pathological stages, biopsy and pathological Gleason score, and serum testosterone levels within 3 months before treatment if available. Blood was obtained from patients between 8:00 AM and 10:00 AM, and serum testosterone level was measured by an electrochemiluminescence immunoassay method. Neoadjuvant ADT was performed mainly for the following reasons: (1) initiation in previous institutions; (2) high-risk prostate cancer; and (3) volume reduction for large prostate. Patients were treated by neoadjuvant ADT with surgical castration or medical castration using a luteinizing hormone-releasing hormone agonist (goserelin acetate or leuprorelin acetate)/antagonist (degarelix acetate) and/or an anti-androgen agent (bicalutamide, flutamide, or chlormadinone acetate). Of these, 49, 9, and 17 patients were treated with combined androgen blockade by castration with anti-androgen agent, castration alone, and anti-androgen agent alone, respectively. The median duration of neoadjuvant ADT was 4 months (interquartile range, 2–8 months). BCR was defined as absent for postoperative PSA levels <0.2 ng/mL, or present in the event of two consecutive postoperative PSA levels ≥0.2 ng/mL.

2.3. Statistical analysis

All statistical analyses were performed using the JMP11 software (SAS Institute, Cary, NC, USA). BCR-free survival was determined by the Kaplan–Meier method, and the log-rank test was used to compare survival durations across risk groups. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model to estimate the hazard ratio. The predictive role of subgroup for recurrence-free survival (RFS) of neoadjuvant ADT was investigated by the interaction test. Correlations between parameters were examined by Pearson Chi-square test or Wilcoxon rank sum test. All P values were two-sided, and P values < 0.05 were considered significant.

Table 1

| Variable | All (n = 711) | Neoadjuvant ADT | P |
|----------|--------------|-----------------|---|
|          | Not performed (n = 636) | Performed (n = 75) |   |

| Median age, y (IQR) | 66 (61–70) | 66 (61–70) | 67 (63–70) | 0.25 |
| Median PSA at diagnosis, ng/mL (IQR) | 7.9 (5.6–12.2) | 7.8 (5.5–11.9) | 10.3 (6.7–15.5) | 0.0013 |
| Biopsy Gleason score, n (%) | 7 | 4 | 3 |   |
| <7 | 251 (37.1) | 231 (37.7) | 20 (31.7) |   |
| 7 | 309 (45.7) | 281 (45.8) | 28 (44.4) |   |
| >7 | 116 (17.2) | 101 (16.5) | 15 (23.8) | 0.31 |
| NA | 35 | 23 | 12 |   |
| Clinical T-stage, n (%) |   |   |   |   |
| cT1/2a | 536 (81.6) | 487 (82.1) | 49 (76.6) |   |
| cT2b | 46 (7.0) | 44 (7.4) | 2 (3.1) |   |
| cT2c/3 | 75 (11.4) | 62 (10.5) | 13 (20.3) | 0.0025 |
| NA | 54 | 43 | 11 |   |
| Surgical procedures, n (%) |   |   |   |   |
| Open RP | 317 (44.6) | 278 (43.7) | 39 (52.0) | 0.38 |
| Laparoscopic RP | 92 (12.9) | 83 (13.1) | 9 (12.0) |   |
| Robot-assisted RP | 302 (42.5) | 275 (43.2) | 27 (36.0) |   |
| Pathological Gleason score, n (%) |   |   |   |   |
| <7 | 131 (21.3) | 131 (21.3) | — |   |
| 7 | 425 (69.1) | 425 (69.1) | — |   |
| >7 | 59 (9.6) | 59 (9.6) | — | NA |
| NA | 96 | 21 | 75 |   |
| Pathological T-stage, n (%) |   |   |   |   |
| pT0 | 12 (1.7) | 4 (0.6) | 8 (11.9) |   |
| pT2 | 473 (68.7) | 427 (68.7) | 46 (68.7) |   |
| pT3 | 199 (28.9) | 186 (29.9) | 13 (19.4) |   |
| pT4 | 5 (0.7) | 5 (0.8) | 0 (0.0) | <0.0001 |
| NA | 22 | 14 | 8 |   |

ADT, androgen-deprivation therapy; IQR, interquartile range; NA, not available; PSA, prostate-specific antigen; RP, radical prostatectomy.

a) Statistically significant.
3. Results

3.1. Patient characteristics

This study included 711 Japanese men who underwent RP for prostate cancer. During the median observation period of 2.2 years (interquartile range, 0.8–4.9 years), a total of 186 (26.2%) patients experienced BCR. As shown in Table 1, PSA levels at diagnosis were higher and advanced T-stage was more prevalent in the neoadjuvant group (75 patients), reflecting the preferred introduction of neoadjuvant ADT for high-risk prostate cancer. Pathological T-stage was lower in the neoadjuvant group, in which pT0 was observed in 8 (11.9%) of 75 patients who had undergone neoadjuvant ADT due to tumor regression by ADT. However, the BCR-free survival rate was lower in patients treated with neoadjuvant ADT (median RFS, 6.4 years) than in those treated without neoadjuvant ADT (median RFS, not yet reached), although the difference was statistically insignificant (Fig. 1, Table 2), reflecting the difference in the clinicopathological background between patients treated with and without neoadjuvant ADT.

3.2. Subgroup analysis for RFS

Next, we performed subgroup analyses for RFS using various clinicopathological parameters. As shown in Table 2, in patients aged >65 years, RFS was lower in patients treated with neoadjuvant ADT than in those treated without neoadjuvant ADT [hazard ratio (95% confidence interval), 2.04 (1.13–3.43), P = 0.020]. Furthermore, among the patients aged >65 years, the Kaplan–Meier curve showed reduced RFS in patients treated with neoadjuvant ADT compared with those treated without neoadjuvant ADT (log-rank test, P = 0.0098, Fig. 2A), suggesting an adverse role of neoadjuvant ADT in older patients. The interaction between neoadjuvant ADT and age on RFS was statistically marginal (P = 0.066). There was no difference in clinicopathological parameters between patients treated with or without neoadjuvant ADT.

| Variable               | Neoadjuvant ADT (−)/(+) | HR (95% CI) a) | P     | Interaction |
|------------------------|-------------------------|----------------|-------|-------------|
| All patients           | 636/75                  | NYR/6.4        | 1.43  | 0.12        | —           |
| Age, y                 |                         |                |       |             |             |
| ≤65                    | 311/35                  | NYR/NYR        | 0.92  | 0.81        | P = 0.066   |
| >65                    | 325/40                  | 11.3/3.3       | 2.04  | 0.020 b)    |             |
| PSA at diagnosis, ng/mL|                         |                |       |             |             |
| ≤10                    | 420/35                  | NYR/5.1        | 1.59  | 0.24        | P = 0.51    |
| >10                    | 212/37                  | 9.9/4.5        | 1.11  | 0.72        |             |
| Biopsy Gleason score   |                         |                |       |             |             |
| <7                     | 231/20                  | NYR/NYR        | 1.37  | 0.62        | P = 0.88    |
| ≥7                     | 281/28                  | NYR/6.4        | 1.16  | 0.71        |             |
| Clinical T-stage       |                         |                |       |             |             |
| cT1c2a                 | 487/49                  | 11.3/NYR       | 1.24  | 0.50        | P = 0.90    |
| cT2b                   | 44/2                    | 2.7/NYR        | 1.04  | 0.97        |             |
| cT2c3                  | 62/13                   | 2.2/3.3        | 0.85  | 0.73        |             |

ADT, androgen-deprivation therapy; CI, confidence interval; HR, hazards ratio; NYR, not yet reached; PSA, prostate-specific antigen; RFS, recurrence-free survival.

a) Reference is neoadjuvant ADT (−).

b) Statistically significant.
parameters among patients aged >65 years between those treated with and without neoadjuvant ADT (Supplementary Table 1).

3.3. RFS stratified by serum testosterone levels before treatment

To explore the possible reason of this differential RFS between patients aged >65 years with and without neoadjuvant ADT, we next investigated serum testosterone levels before treatment, which is well known to be adversely associated with age and a prognostic factor of ADT for metastatic prostate cancer. Among the total 711 patients included in this study, serum testosterone levels before treatment were available in 53 patients only. Intriguingly, the Kaplan–Meier curve analysis in patients with serum testosterone levels ≤450 ng/dL showed significantly worse RFS when treated with neoadjuvant ADT than when not treated with neoadjuvant ADT (log-rank test, P = 0.020, Fig. 2B).

Fig. 2. Biochemical recurrence-free (BCR) survival in patients treated with radical prostatectomy divided into subgroups. (A) BCR-free survival of patients aged ≤ 65 years or > 65 years. (B) BCR-free survival of patients with serum testosterone level before ADT ≤ 450 ng/dL or > 450 ng/dL, with or without neoadjuvant ADT. ADT, androgen-deprivation therapy.
In contrast, the Kaplan-Meier curve analysis in patients with serum testosterone levels >450 ng/dL showed marginally superior RFS when treated with neoadjuvant ADT compared with those treated without neoadjuvant ADT (log-rank test, \( P = 0.082, \) Fig. 2B). Furthermore, the interaction between neoadjuvant ADT and serum testosterone levels on RFS was statistically significant (\( P = 0.011 \)), suggesting that the effect of neoadjuvant ADT may be dependent on serum testosterone levels before ADT.

4. Discussion

To date, no biomarker for identifying prostate cancer patients who are suitable for neoadjuvant ADT has been identified. Here we identified age as well as serum testosterone levels before treatment as possible biomarkers to identify candidates suitable for neoadjuvant ADT.

Intriguingly, both age and serum testosterone levels before treatment have been reported as being possible prognostic markers in ADT. Young age was associated with a worse prognosis in patients with metastatic prostate cancer treated with ADT in previous studies using a population-based database across different races and nations,21–23 in contrast with RP and radiotherapy,24 suggesting the uniqueness of age in therapeutic sensitivity to ADT. Low serum testosterone levels before treatment may represent a reduced androgen dependency of the prostate cancer, which would be less effectively repressed by ADT. Serum testosterone level has also repeatedly been shown to be prognostic in patients with metastatic prostate cancer treated with ADT,7–20 which may be due to high malignant potential in patients with lower serum testosterone levels.25 Thus, both age and serum testosterone level may be common predictive markers for the efficacy of ADT and may serve as parameters for selection of candidates suitable for neoadjuvant ADT.

Since serum testosterone level is known to decline with age,16 age may affect the sensitivity to ADT through serum testosterone levels. In addition, because an improvement of RFS was suggested by neoadjuvant ADT in patients with serum testosterone levels >450 ng/dL and a clear inverse association between serum testosterone level and effect of neoadjuvant ADT was shown, serum testosterone levels would be an attractive biomarker to identify candidates suitable for neoadjuvant ADT. This suggests that a clinical trial including patients with high serum testosterone levels to compare outcome by RP with or without neoadjuvant ADT would be intriguing. However, the study has several limitations, and validating studies using existing data are thus required before initiating such clinical trials. In this study, the observation period was relatively short for observing BCR, the sample size was small, and the study design was retrospective. RP was performed by several surgeons, and neoadjuvant ADT used in a limited number of cases varied in mode and term. Moreover, serum testosterone levels before ADT were available in only a limited number of patients.

To the best of our knowledge, this study suggested for the first time that neoadjuvant ADT showed potential deleterious effects in older patients and patients with lower serum testosterone levels, while a possible improved prognosis was suggested for patients with high serum testosterone levels treated with neoadjuvant ADT. Further exploration of these parameters on prognosis in neoadjuvant ADT with RP is warranted.

Conflicts of interest

We declare no conflicts of interest.

Grant support

This work was supported by Kakenhi grants (17K11145) from The Ministry of Education, Culture, Sports, Science, and Technology of Japan, Research Promotion Grant from the Takeda Science Foundation, and Research Promotion Grant from Shin-Nihon Advanced Medical Research.

Acknowledgments

We would also like to thank Edanz Group Japan for their editorial assistance.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.prnil.2017.10.002.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2015;2015(65):5–29.
2. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical pros-
tectomy for locally advanced prostate cancer: current status. Urology 2015;86:10–5.
3. Pound CR, Partin AW, Eisenberger MA, Pound CR, Partin AW, Eisenberger MA.
Natural history of progression after PSA elevation following radical pros-
tectomy. JAMA 1999;281:1591–7.
4. Simmons MN, Stephenson AJ, Heim EA. Natural history of biochemical recur-
rence after radical prostatectomy: risk assessment for secondary therapy. Eur
Urol 2007;51:1175–84.
5. Bach C, PopSipari S, Daneshwar D, Wright M, Rowe E, Gillatt D, et al. The status of surgery in the management of high-risk prostate cancer. Nat Rev Urol 2014;11:
342–51.
6. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al.
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomised clinical trial. J Urol 2009;181:956–62.
7. Messing EM, Manola J, Yao J, Kienman M, Crawford D, Wilding G, et al. Imme-
diate versus deferred androgen deprivation treatment in patients with node-
positive prostate cancer after radical prostatectomy and pelvic lymphadenec-
tomy. Lancet Oncol 2006;7:472–9.
8. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of
estradiol and androgen injection on serum phosphatases in metastatic carci-
noma of the prostate. Cancer Res 1941;1:293–7.
9. Soloway MS, Pareek K, Shariff R, Wajsman Z, McLeod D, Wood Jr DP, et al.
Neoadjuvant androgen ablation before radical prostatectomy in T2bN0M0 prostate cancer: 5-year results. J Urol 2002;167:112–6.
10. Aus C, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al.
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a
treatment of four months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170:791–4.
11. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and
adjuvant hormone therapy for localised and locally advanced prostate cancer.
Cochrane Database Syst Rev 2006;4CD006019.
12. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radia-
tion therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
13. Naito S, Ujiwaka K, Kimizuka M, Goto K, Koga H, Ogawa O, et al. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopath-
ological Research Group for Localized Prostate Cancer. J Urol 2008;180:904–9.
14. Shiotani M, Fujimoto T, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, et al. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism. Prostate Cancer Prostatic Dis 2016;19:191–6.
15. Feldman HA, Longcope C, Deriba CA, Johannes CR, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-
aged men: longitudinal results from the Massachusetts male aging study. J Clin
Endocrinol Metab 2002;87:589–98.
16. Cantisani GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent
prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991;265:618–21.
17. Matzkin H, Perito PE, Soloway MS. Prognostic factors in metastatic prostate cancer. Cancer 1995;72:3788–92.
19. Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001;48:573–8.
20. Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, et al. Prognostic impact of serum testosterone and body mass index before androgen-deprivation therapy in metastatic prostate cancer. Anticancer Res 2015;35:6925–32.
21. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 2007;110:81–6.
22. Cetin K, Beebe-Dimmer JL, Fryzek JP, Markus R, Carducci MA. Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the surveillance, epidemiology, and end results program. Urology 2010;75:1396–404.
23. Kimura T, Onozawa M, Miyazaki J, Matsuoka T, Joraku A, Kawai K, et al. Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. Int J Urol 2014;21:578–83.
24. Hotston MR, Burden H, Thurairaja R, McFarlane J, Persad RA. Young men with prostate cancer: are they different and how should they be managed? BJU Int 2007;99:5–7.
25. Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res 2008;28:2487–92.